- Home
- IKNA vs CTMX Comparison
IKNA vs CTMX Comparison
Compare IKNA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- CTMX
- Stock Information
- Founded
- IKNA 2016
- CTMX 2008
- Country
- IKNA United States
- CTMX United States
- Employees
- IKNA N/A
- CTMX N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- CTMX Health Care
- Exchange
- IKNA Nasdaq
- CTMX Nasdaq
- Market Cap
- IKNA 61.8M
- CTMX 60.7M
- IPO Year
- IKNA 2021
- CTMX 2015
- Fundamental
- Price
- IKNA $1.13
- CTMX $0.93
- Analyst Decision
- IKNA Buy
- CTMX Buy
- Analyst Count
- IKNA 2
- CTMX 5
- Target Price
- IKNA $3.00
- CTMX $5.52
- AVG Volume (30 Days)
- IKNA 96.4K
- CTMX 2.4M
- Earning Date
- IKNA 05-08-2025
- CTMX 05-12-2025
- Dividend Yield
- IKNA N/A
- CTMX N/A
- EPS Growth
- IKNA N/A
- CTMX N/A
- EPS
- IKNA N/A
- CTMX 0.38
- Revenue
- IKNA N/A
- CTMX $138,103,000.00
- Revenue This Year
- IKNA N/A
- CTMX N/A
- Revenue Next Year
- IKNA N/A
- CTMX N/A
- P/E Ratio
- IKNA N/A
- CTMX $2.46
- Revenue Growth
- IKNA N/A
- CTMX 36.45
- 52 Week Low
- IKNA $0.97
- CTMX $0.40
- 52 Week High
- IKNA $1.94
- CTMX $2.81
- Technical
- Relative Strength Index (RSI)
- IKNA 43.57
- CTMX 61.33
- Support Level
- IKNA $1.22
- CTMX $0.63
- Resistance Level
- IKNA $1.29
- CTMX $1.04
- Average True Range (ATR)
- IKNA 0.09
- CTMX 0.11
- MACD
- IKNA -0.01
- CTMX 0.03
- Stochastic Oscillator
- IKNA 23.33
- CTMX 44.95
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.